Lysoway Therapeutics
Biotechnology Research
245 1st St
6 employees
- Employees
- 6
- Contacts
- 2
- Emails
- 2
Lysoway Therapeutics Overview
- Headquarters
- 245 1st St
- Website
- www.lysoway.com
- Industry
- Biotechnology Research
- Employees
- 6
- Founded
- 2020
- Funding
- 2.9M
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About Lysoway Therapeutics
Lysoway Therapeutics has developed unique technological approaches to screen and develop potent modulators of lysosomal ion channels, including TRPML1 and TMEM175. These small-molecule compounds can restore autophagic flux and resolution, as well as enhance plasma membrane repair through direct activation of lysosomal exocytosis. These modulators have great potential to treat neurodegenerative diseases with age-related decline of autophagy/lysosomal function or rare diseases characterized by toxic accumulation of cellular wastes.
Lysoway Therapeutics Contact Details
- People in AeroLeads
- 2
- With contact data
- 2
- Email contacts
- 2
- 100.0% coverage
Lysoway Therapeutics Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Valerie Cullen | United States |
Email
|
|
| S. Frank Yan | Shanghai, China |
Email
|
Compare Similar Companies to Lysoway Therapeutics
Denali Therapeutics
Biotechnology Research
Dyne Therapeutics
Biotechnology Research
Alkeus Pharmaceuticals, Inc.
Biotechnology Research
Cellular Pharmacology - Sygnature Discovery
Biotechnology Research
Congruence Therapeutics
Biotechnology Research
Tenvie Therapeutics
Biotechnology Research
SiSaf Ltd
Biotechnology Research
The Silverstein Foundation for Parkinson's with GBA
Research Services
Eumentis Therapeutics Inc.
Biotechnology Research
Threebrooks Therapeutics Inc
Biotechnology Research